Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.39 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | BRS3 | P32247 | 3/20 | 0.37 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28769964 | 0.90 | AGTR1 (0.36) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL6081463 | 0.87 | AGTR1 (0.35) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL6081457 | 0.86 | AGTR1 (0.36) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL27371509 | 0.85 | BRS3 (0.32) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL6082737 | 0.81 | BRS3 (0.35) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL6953051 | 0.77 | HSD11B1 (0.47) | AGTR1AGTR2BRS3 | |
| SCHEMBL9251216 | 0.75 | AGTR1 (0.36) | AGTR1AGTR2 | |
| SCHEMBL15310211 | 0.75 | AGTR1 (0.35) | AGTR1AGTR2BRS3 | |
| SCHEMBL3347428 | 0.74 | GP6 (0.54) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| SCHEMBL7050688 | 0.74 | AGTR1 (0.34) | AGTR1AGTR2ABCC4ABCB11PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106034-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100298277-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298277-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR1, AGTR2, NR3C2 | AGTR1 1/4885AGTR2 2/4885ABCC4 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.